Rankings
▼
Calendar
URGN Q1 2021 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
Gross Profit
$7M
88.0% margin
Operating Income
-$26M
-348.9% margin
Net Income
-$26M
-346.5% margin
EPS (Diluted)
$-1.17
QoQ Revenue Growth
-6.0%
Cash Flow
Operating Cash Flow
-$27M
Free Cash Flow
-$28M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$97M
Total Liabilities
$21M
Stockholders' Equity
$76M
Cash & Equivalents
$40M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$7M
$0
—
Gross Profit
$7M
$0
—
Operating Income
-$26M
-$39M
+32.3%
Net Income
-$26M
-$38M
+31.4%
← FY 2021
All Quarters
Q2 2021 →